<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102674</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-CAN-04-02</org_study_id>
    <nct_id>NCT00102674</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor</brief_title>
  <official_title>The Pharmacokinetics and Pharmacodynamics of a Cangrelor Bolus Plus Infusion in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <brief_summary>
    <textblock>
      The purposes of this study are to:&#xD;
&#xD;
        -  Evaluate the tolerability of two cangrelor regimens.&#xD;
&#xD;
        -  Compare the PD of cangrelor regimens with oral clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of this study are:&#xD;
&#xD;
        -  To evaluate the tolerability of two cangrelor regimens of bolus plus infusion (A and B).&#xD;
&#xD;
        -  To characterize the pharmacokinetics of Cangrelor (A and B).&#xD;
&#xD;
        -  To compare the pharmacodynamics of cangrelor regimens with that of an oral 600 mg dose&#xD;
           of clopidogrel (A, B, C and D).&#xD;
&#xD;
        -  To determine the effect of prior cangrelor treatment on the pharmacodynamics of&#xD;
           clopidogrel (C and D).&#xD;
&#xD;
        -  To determine the effect of prior clopidogrel treatment on the pharmacodynamics of&#xD;
           cangrelor (Group D).&#xD;
&#xD;
        -  To determine the effects of concomitant clopidogrel and cangrelor exposure on the&#xD;
           pharmacodynamics of clopidogrel (Group D).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date>May 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the tolerability of two cangrelor regimens</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cangrelor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent before initiation of any study related procedures.&#xD;
&#xD;
          -  Age 18 - 55 years&#xD;
&#xD;
          -  Normal findings on physical examination.&#xD;
&#xD;
          -  A normal 12-lead ECG and normal vital signs (blood pressure, heart rate), unless any&#xD;
             abnormality was considered clinically irrelevant by the investigator.&#xD;
&#xD;
          -  Normal laboratory and hematology values unless the investigator considered an&#xD;
             abnormality to be clinically irrelevant.&#xD;
&#xD;
          -  Negative test for pregnancy as determined by urinary b-HCG prior to the administration&#xD;
             of study drug for all females of child-bearing potential.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 20 and 25 kg/m2 based on actual body weight.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of or presence of renal, hepatic, neurological, hematological,&#xD;
             gastrointestinal, or psychiatric disease or other condition known to interfere with&#xD;
             the absorption, distribution, metabolism or excretion of drugs.&#xD;
&#xD;
          -  Hypersensitivity to clopidogrel or cangrelor (or the excipients therein).&#xD;
&#xD;
          -  Symptoms of a clinically significant illness, or surgery or trauma within 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Donation of blood or plasma totaling more than 500 mL within the 3 months preceeding&#xD;
             the study.&#xD;
&#xD;
          -  A significant history of alcohol or drug abuse, a positive urine drug screen, tobacco&#xD;
             use within the 3 months preceding enrollment, or alcohol ingestion within 48 hours of&#xD;
             dosing.&#xD;
&#xD;
          -  A history of hepatitis or human immunodeficiency virus (HIV) or exposure thereto.&#xD;
&#xD;
          -  Use of any prescribed medications in the 2 weeks prior to dosing, any aspirin or&#xD;
             naproxen-containing medication within 2 weeks of dosing, use of acetaminophen within&#xD;
             24 hours or ibuprofen, vitamins or dietary supplements within 48 hours of dosing (oral&#xD;
             contraceptives are permitted).&#xD;
&#xD;
          -  Personal or family history of coagulation or bleeding disorders, or reasonable&#xD;
             suspicion of vascular malformations, including aneurysms; history of important&#xD;
             bleeding, (i.e. hematemesis, rectal bleeding, melena, severe or recurrent epistaxis,&#xD;
             hemoptysis or intracranial hemorrhage), history of head injury or intracerebral&#xD;
             disease, or recent or planned spinal or epidural puncture.&#xD;
&#xD;
          -  Significant epigastric pain or &quot;indigestion&quot;, either chronically or within 4 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          -  Diagnosed hypertension, or supine blood pressure at or above 150/90 mmHG or less than&#xD;
             100/50 mmHg at screening.&#xD;
&#xD;
          -  Participation in any clinical study with an investigational new drug in the 3 months&#xD;
             prior to dosing in the study or participation in a study with a new formulation of a&#xD;
             marketed drug in the previous 3 months.&#xD;
&#xD;
          -  Anemia or thrombocytopenia (values on screening hematology less than the reporting&#xD;
             laboratory's lower limit of normal).&#xD;
&#xD;
          -  Any other characteristic or condition which, in the opinion of the investigator, makes&#xD;
             participation in this study inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Steinhubl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>January 31, 2005</study_first_submitted>
  <study_first_submitted_qc>January 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2005</study_first_posted>
  <last_update_submitted>August 15, 2011</last_update_submitted>
  <last_update_submitted_qc>August 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <keyword>cangrelor</keyword>
  <keyword>clopidogrel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

